Merkel cell carcinoma (MCC) is a rare and aggressive epidermal cancer. We conducted a retrospective study and literature review to investigate the impact that radiation therapy has on local, regional, and distant control aspart of the oncologic managementofMCC of the headand neck and tofurther elucidate the role of radiation therapy with regard toregional controlfor theclinically uninvolved neck.
with theFisherexact test; Kaplan -Meieranalysiswas used to reportactuarialcontrol data. StageI toIII headand neck MCC was identifiedin36patients-22menand14 women, aged43 to97years (mean:71.6) at diagnosis. Patientswith stage I and II tumors were combined into one group, and theirdata were compared with those ofpatients with stage III tumors. Twenty-sixpatients(72%) hadclinical stageI/II disease and 10patients (28%) hadclinical stageIII disease. Median follow-up was 41 monthsfor the stage [III group and 19monthsfor thestageIIIgrollp. Basedonexamination at final [ollow-up visits, local recurrence was seen in 7 of the 36 patients (19%), for a local control rateof 81%. The 2-yearactuarial local control rateforallstagesofMCC was 83%; by treatment subgroup, the rates were 95% for those who had undergone radiation therapy to the primary site and 69% for those who had not-a statistically significant difference (p =0.020). Based on information obtained at finalfollow-ups, 10 of the36 patients (28%) experienced a regional recurrence,for a regional control rate of72%. The 2-year actuarial regional control rate among all patients was 70%; by subgroup, rates were 82% for patients who had undergone regional node radiation therapy and 60% for those whohad not-not a statisticallysignificantdifference (p = 0.225). Nine patients (25%) overall developed a distantmetastasis,foradistantcontrol rateof75%. Salvage therapies included chemotherapy and/orradiation therapy to the metastaticsite, but neitherhad any significanteffect on survival. Regardless of treatment, the Kaplan-Meier survivalcurves leveled off at 30 monthswith 82% survival for thestage[/II groupand at 19 monthswith 60% survival for thestage III group. We conclude that radiation therapy Introduction Merkel cell carcinoma (MCC) is a rare, aggressive neuroendocrine skin cancer with an estimated age-adjusted incidence of0.24 per 100,000 person-years.' MCC commonlypresents in sun-exposed areas in elderly patients; approximately 50% of all cases arise in the head and neck region.' Unlike other nonmelanoma skin cancers, MCC has a high propensity for regional and distant metastasis, and it is associated with a mortality rate of approximately 25 to 30%. 3 Because MCC also has a high propensity for local recurrence, the treatment of choice for the primary lesion iswide local excision . However, this approach is not always functionally possible or cosmetically desirable in the head and neck region. Therefore, radiation therapy is often used as a definitive or adjuvant therapy to the primary tumor, with or without treatment of regional lymph nodes.
Although radiation therapy is often employed, its impact on locoregional control and survival in the treatment ofMCC of the head and neck, as well as other body sites, is unclear, as there is a lack of high -level evidence from controlled trials. Still, there are two recently published retrospective series that did address the role of adjuvant radiation therapy to the tumor bed in head and neck MCC .JA The results of these studies suggested that combined therapy was associated with good local control and a disease-specific survival advantage.
Another important aspect of MCC is its infiltrative histologic pattern, which often leads to tumor spread through dermal lymphatics and results in a high risk of microscopic tumor in clinically uninvolved tissue and occult nodal metastasis.' Therefore, the role of radiation therapy for regional node beds needs to be addressed.
The primary aims of this study were (1) to determine the impact that radiation therapy to the primary site and regional lymph nodes had on local, regional, and distant control in patients with MCC of the head and neck and (2) to further elucidate the role of radiation therapy in the setting of a clinically uninvolved neck.
Patients and methods
For this retrospective study, we reviewed all registered cases of MCC of the head and neck that were treated Data were collected on patient and tumor characteristics, treatment variables, and outcomes (table 1) . Patient characteristics were sex and age at diagnosis. Tumor characteristics included primary tumor site and size,clinical and/or pathologic stage at presentation, and disease status at 2 years and at the time of the last followup. The treatment variables included the means oflocal management of the primary lesion (e.g., surgery and/ or radiation therapy), the margin status of the resected specimen, the type of management ofthe draining nodal basin (e.g., surgery and/or radiation therapy) , the use or nonuse of systemic chemotherapy, the incidence of local and regional recurrence and distant metastasis, and survival. Only patients with stage I, II,or III tumors, according to theAmerican Joint Committee on Cancer's 2002 criteria (table 2) ,6 were included in this review; patients with stage IV disease (distant metastasis) were not included in this analysis.
For the purpose ofthis study, patients withAJCC stage I and II cancers were combined into one subgroup. The stage IIII cases were analyzed separately from the stage III cases so that we could more clearly delineate the effects of radiation therapy on patients with and without nodal involvement. Local, regional, and distant failure rates were evaluated by comparing variables according to the Fisher exact test. Local failure was defined as a recurrence ofMCC in the same area as the primary site, and regional failure was defined as a recurrence in the draining lymph nodes or in proximity ofthe primarysite. Kaplan-Meier analysiswas used to report actuarial failure data and overall survival based on stage and treatment. The log-rank test was used to compare survival rates.
Statistical significance was considered at the p s; 0.05 level.This study was approved by the institutional review boards of all four institutions.
Results
Patient and tumor characteristics. Stage Key: Pt = patient IlUmber; Pathol = pathologic; XRTp = radiation therapy to the primary site; XRTn = radiation therapy to regional lymph nodes; LND = lymph node dissection; Chemo = chemotherapy; LF = local failure; RF = regional failure; DF = distant failure; DOD = died of disease; N/A= not applicable, 
Years afte r diagnosis
Fi gure 1. Actuarialanalysisoflocalrecurrencesof allstagesofMCC reveals that local control rates weresignifica ntly higher in patients whohadundergoneradiatio ntherapy totheprimary tumor(XRTp) than in those who had not (p = 0.020). were found to be pN+ (the path ology report on th e th ird patient was n ot foun d) . Of th e 10 patient s who underwent lymph nod e dissection , 4 of the 7 stage IIII patients (includ ing th e 2 pN+ patients) and 2 of th e 3 stage III patients had received rad iation therapy to the regional lymph nod es (table 1) .
Localcontrol.The 2-year actuarial local control rate for all stages ofMCC was 83%. Patients who had undergone primary site radiation therapy had a signifjcantly higher local control rate at 2 years than did those who had not (95 vs. 69%; p= 0.020) (figur e 1). Based on information available at final follow-up visits, 7 of the 36 patients (19% ) experience d a local recurrence, for an overall local control rate of 81% (table 3) . Six of these failures occurred within the first year, and the other at 8 years ; the median time to local recurrence was 179 days (range: 90 to 2,958) . Only 1 of the 7 local failures occurred in a patien t with stage III disease (table 1) .
Stage l lII. A subgroup ana lysis of stage IIII patients revealed th at th e 2-year actuarial local con trol rate was 73% for th e stage I patients an d 91% for th e stage II pa tients-no t a statistically significan t differen ce (p = 0.225). There appeared to be no relationship between margin stat us and local recurrence. Of the 3 Treatment of the p rimary tumor and the nodal region. Primary site resect ion had been performed in 30 pat ients; resection was not performed in 5 pa tients and excision status was unkn own in 1. Of th e 30 pati ents, surg ical m argins were positive in 4 patien ts (3 at stage IIII an d 1 at stage III ) and un known in 2 patients (both stage 1III) . Of th e 30 patients, 16 had received radiatio n th erapy to th e primary site. Th e m edian postoperative radiation the rapy dose was 54.5 Gy (range: 39 to 60.9 Gy). Three of the 4 patient s who had positive m argins had received adjuvant rad iation therapy to th e prim ary site (range: 39 to 60 Gy). Of the 5 patients with unresected primary disease, 4 received radiation th erapy to the primary site (m edian dose: 52.5 Gy; range: 51 to 70.2); the pa tien t whose excision status was unkn own did not receive such therapy (table 1) .
Of the 26 patients with clinical stage lin disease, 23 (88%) had undergone primarysite resection bywide local excision an d 2 (8%) had not; no surgical information was availab le on the remaining patient. Twelve of the 26 patients (46% ) had received radiation therapy to the primarysite. Of th e 23 pat ients who had undergone wide local excision , 18 (78%) had negative surgical margins and 3 (13%) had positive m argins; the m argin stat us of the rema ining 2 patients (9%) was unknown. Of the 3 patient s who had positive m argins, 2 had undergon e radiation therapy to both th e prim ary tumor and th e regional lymph nod es, an d the other ha d undergone neith er (table 1) .
Among the 10 patients with clinical stage III disease , 7 had undergone primary site resection via wide local excision; 6 of them (86% ) had negative margins and 1 (14%) had posi tive margins. Eight of the 10 stage III pat ients had received radiation therapy to the primary site (table 1) .
Of the 36 patients, 17 (47%) had undergone radiation therapy to the regional lymph nodes; of these, 8 had clin ical stage lin disease and 9 had clinical stage III disease . The m edian radiation dose to the regional nodes was 51 Gy (range:38.5 to 70.2 Gy). Elective lym ph node dissec tion was performed on 7 of the 26 stage IIII pa tients (27%) and 3 of the 10 stage III patients (30%) . In all, 7 of these 10 pa tien ts had clinica lly un involved nod es (cNO) and 3 had clinica lly involved nod es (cN + ).
Of th e 7 cNO patien ts, 2 were found to have path ologically invo lved nod es (pN +) ; of th e 3 cN+ patien ts, 2 Key: WLE = wide local excision; XRT = radiation therapy; N/A = not applicabl e. Table 3 . Local recurrence stratified by t he type of treatment to the primary site and the presence or absence of adjuvant chemotherapy stage I/II patients who had positive margins after wide local excision , none experienced a local recurrence; 2 of these patients had also received radiation therapy to both the primary tumor and th e regio nal lymph no des. Of the 18 stage VII patients who had negat ive surgica l margins after wide local excision, S experienced a local recurrence. The 2 patients in thi s group who did not have wide local excision performed did not experie nce a local failure . Local control rates in the stage VII patients were 100% (12/12) for those who received radiation therapy to the primary site and 57% (8/14) for those who did not-a statistically significant difference (p = 0.0 17) (figure 2). Five of the 6 patients who experienced a local recurrence underwent re-excision of the tumor, and 5 received radiation therapy (median do se: 54 Gy; range : 50 to 67.5).
Stage III.Only 1of the 10 stage III patients experienced a local recurrence. That 1 patient had been tre ated with wide local excision and radiation therapy to the primary site.The patient subsequently un derwen t salvage therapy with additio nal radiation therapy (66 Gy). There was no statistically significant difference in local control rates bet ween stage III patients who did and did not receive primary site radiation therapy (88 an d 100%, respectively; p = 1.000).
Regional control. Ten of the 36 patients (28%) experienced a regional failure (table 1). The median time to regional recurrence was 242 days (range 90 to 733). The overall 2-year actuarial regional control rate was 70%-82% for those who had received regional node radiation therapy and 60% for those who had not (p = 0.225) (figur e 3).There was no significant difference in con trol between patients who had undergone lymph no de dissectio n with or without rad iation therapy to the regional nodes and th ose whose nodes had been treated on ly with radi ation therapy (80 and 82%, respecti vely; p = 1.000.)
StageIIII. Of the 26 patients in the stage VII group, 8 (31%) experie nced a regional recurrence; on ly 1ofth ese patients had received radiation th erapy to the regiona l lymph nodes . In all, 8 patients had received radiation therapy to the regional lymph nodes ,and on ly 1 of them had exper ienced a regional recurrence. Salvage thera py included additional radiation th erapy (54 Gy).
Four stage VII patients had undergone both lymp h node dissection and radiation ther apy to the nodes, and none experienced a regional recurrence (table 4) . There was no significant difference in regional control rate s according to the presence or absence of regional node rad iation therapy (87 and 61%, respectively; p = 0.36).
Stage III. Two th erapy to the region al nodes. All 7 stage III patients who had not undergon e lymph node dissection received radiation therap y to th e nod es; only 1 of th em expe rienced a region al failur e, and th at patient sub sequentl y underwent lymph nod e dissection. Th ere was no significant differenc e in local control rates amo ng th e stage III patient s who had and had not received regio nal radiation therapy to th e node s (78 and 100%, respectively; p = 1.000). Distant control. Nine of 36 patient s-4 in stage IIII and 5 in stage III-developed a distant meta stasis, for a distant control rateof75% (table 1) .Metast asis involved the liver in 2 pat ients, the liver and kidney in another pati ent, and the brain, lun g, mediastinum, spine, and pancreas in 1 patient each; the rem aining pati ent had widespread metastasis. Th emedian tim e to distant failure was 563 days (range: 240 to 1,511) (table 5).
Salvage therapies included chemotherapy and/or radiation therapy to th e metastatic site. Four of th e 9 patients (44%) with distant metastasis ultimately died of th eir disease; th e remaining 5 patients were alive at th e last follow-up either with or without disease.Neith er chemo therapy no r radiation th erapy to the prim ar y site and/or to th e region al nodes had any significant effect on distant control.
Stage I1II. Among the clinicalstage 1/11 patient s,distan t metastasis occurred in 1 of 12 patients (8%) who had undergon e radiation th erapy to the pr imary site, compared with 3 of 14 patien ts (21%) who had not-not a statistically significant difference (p =0.598). Likewise, dist ant failur e occurred in 0 of 8 pati ent s (0%) who had received radiation th erapy to th e regional lymph nodes and 4 of 18 patients (22%) who had not-again, not a statistically significant difference (p =0.263). those with stage III MCC (60%), although the difference was not statistically significant (p = 0.138); there was no change in survival estimates for stage IIII patients after 30 months and for stage III patients after 19 months ( figure 4) .Univariate associations by contingency tables revealed that primary site resection, primary site radiation therapy, and regional node rad iation therapy did not significantly improve overall survival. Similarly, the use of chemotherapy did not significantly affect overall sur vival.
Discussion
As is the case with most cancers, the most significant prognostic factor for survival and the development of distant metastasis in MCC is the presence of lymph node involvement.' The treatment ofMCC may involve wide local excision, regional lymph no de dissection, radiation therapy, chemotherapy,or combined-modality treatment.
The role of radiation therapyin the treatment ofMCC remains controversial. Authors of single-institution studies have reached conflicting conclusions with regard to adjuvant treatment for locoregional control. Many repo rts have supported the contention that adjuvant radiation therapy improves local'" and locoregional"" control in MCC, but others' S" have no t.Medina-Franco et al reviewed 11 series 0,024 patients) and reported local recurrence rates of 10.5% with radiation therapy and 52.6% without it (p = 0.00001). 9 Others have reported a high local control rate with wide local excision and no radia tion therapy, a finding th at suggests that surgery alone may be adequate for low-risk patients." The National Comprehensive Cancer Network (NCCN) recommends radiation therapy to the primary tumor site, in-transit lymphatics, and draining nodal basins in the case of wide local excision only (i.e., with no sentinel lymph node biopsy [SLNB]), with the size of the dose dependent on ma rgin status. IS The NCCN also recommends radiation therapy to the primary site alone in cases of a negative SLNB result, and it recomm ends radiation therapy to both the primary site and the draining lymph nodes in cases of a positi ve SLNB result or cN+ disease."
Patients considered to be poor surg ical candidates beca use of comorbidities can be treated with rad iation therapy alone .P:" Mortier et al examined patients treated with radiation therapy alone because the head and neck location or comorbidities precluded wide local excision, and they compared these patients with a group of patients treated with conventional surgery radiation therapy (43%) th an in th ose who underwent surge ry alone (14%).4Gillenwater et al repor ted greater locoregional control in patients who received postoperative radiatio n therapy; local recurrence rates were 44% in those who did not receive adjU;ant radiation therapy (n =34) and 12% in those who did (n =26).10
In the retrospective analysis of the literatur e repo rted by Medina-Franco et al (N = 1,024) , the aut hors stro ngly suggeste d that locoregional control was improved wit h radiatio n therapy? Our study demo nstrated a tren d toward higher regional control in patient s who had undergone radiation therapy to the regional lymph nod es th an in th ose who had not (82 and 60%, respectively), altho ugh th e difference was not stat istically significant (p =0.225).
SLNB is a feasible opt ion for pat ient s with MC C because it provides imp ortant pr ognostic information, especially in cNO patients." Studies of head and neck cancer, part icularly melanom a, have shown th at the drainage characteristi cs of th e lym ph atics of th e head and neck are variable and un pr edictable; the reported prevale nce of head and neck lym ph atic dr ainage to sites not predicted clinically ranges from 34 to 84%.21 Because of this , some authors do not recommend SLNB as the standard of care for patients with MCC of th e head and neck ." Stadelmann et al conducted a study of 74 patients wit h either melanoma or MCC of the head and neck who und erwent lymph oscintigraphy; they found a nonl ocalization rate of 6.8%, which they speculate may have been attr ibutable to the inherent difficulty of im aging th e head and neck regio n an d/or possibly th e rapi d rate of dye washo ut via multiple lymphatic dr ainage pathways in this area." Schmalbach et al performed SLNB on 10 patients with head and neckMCC and were and postoperative radiation therapy." They found that only 1of26 pat ients experie nced a recurrence, and there was no statistically significan t difference in overall and disease-freesurvival rates.Their low recurrence rate (4%) may be attributable to the facts that all of their patients had stage I disease and the dose of radia tion (60 Gy) was higher th an what is typically adm inistere d (50 Gy).
Non eth eless, that study dem onstrated th e impressive outcomes of treatin g selected cases of inop erable MCC with radiation mon otherapy. Thi s option can provide a reasona ble degree of local contro l in the treatment of MCC of th e head and neck when wide local excision would be disfiguring. In our study, 4 patients received radiation the rapy to th e primar y site witho ut wide local excision, and none of th em experienced a local recurrence. Still, complete excision of th e entire primary lesion is pr eferr ed whenever possible."
Five-year surviva l in patients with head and neck MCC ranges from 40 to 68%.1 7A head and neck location has been show n to be an independent indicator of an unfavorable prognosis in MCC. 12 Because MCC affects sun -expose d areas, 50 to 55% ofcases occur on the head and neck ." The median size of the tumor at diagnosis in our study and others tends to be less than 2 em, and as many as one-third of patien ts presen t wit h clinically positive adeno pathy,":" Treatment ofMCC in th e head and neck poses many challenges. Wide local excision of the primary site is not always cosmetic ally desirable, and the treatment of region al lymph nodes may behindered byvariable nodal drainage patt erns . In term s of pri mary tr eatment , wide local excision with 2-cm margins has been advocated by some investigators. However, Gillenwater et al compare d MCC patients whose surg ical margins were either less th an 1 em or more than 2 em following wide local excision and found no significant differences in local, regio nal, and distant cont rol rates .10 On the ot her hand, Boyeret al reported that margin status was an important factor for local recur rence, as higher local recurrence rates were associated with positive margin status and larger tumor size." In our study, radiation therapy to the pr imary tumor site, both with and without wide local excision, resulte d in a local control rate of 95%. Only 4 ofour patient s had pos itive marg ins, and non e of them experienced a local recurrence; 3 of th ese patients received radiation th erapy to the pri mary site.
Som e autho rs recommend th at radiation th erapy be administered to achieve locoregional con trol on ly in advanced cases." Veness et al reported greater region al contro l in cN+ patient s who underwent surg ery plus LAWEN DA, ARNO LD, TOKARZ , SILVERSTEIN, BUSSE, MciNT YRE, DESC HL ER, BALDINI, KACHNIC able to ident ify at least one sentinel lymph nod e in every patien t; of the 8 patients whose SLNBs were negative, only 1 experienced a regional recurrence."
A recent study by Allen et al demonstrated that approximately 25% of cNO patients were pN+ and that those who underwent SLNB had better sur vival and regional control rates.13They recommend ed th at all pati entswith localized MCC und ergo SLNB, just as called for in th e NCCN guide lines.IS They did not find any additional benefit to adjuvant radiation therapy in pat ients with negat ive margins or following SLNB, bu t this is an area ofcontrove rsy and has been disputed by other gro ups ." In the study by Allen et al, only 17% of patient s with local or locoregion al disease received adjuvant radiation therapy,and onl y 6% received radiation therapy to both the surgical bed and the nodal basin.13 With such small percentages, appropriate statistical ana lysis with regard to radiation therapy is challenging.
The repo rted pr evalence of nod al metastasis in th e head and neck at the time of prese ntatio n has range d from 11% 10 to more than 50%. 24 Gillenwater et al showed a 79% regional recurrence rate in cNOpatients.'? Schmal bach et al reported that the presence of nodal disease reduc ed 5-year surviva l rates from 88 to 48%.13 Local tr eatm ent alone do es not address th e cNO neck. In clinically no de-negative (cN-) patients, data suggest that th e risk of occult disease is significan t eno ugh to warrant treatment with SLNB, lymph no de dissection, radiation therapy, or combined treatment.' However, Allen et al repo rted th at in patients with cN+ disease, th e incid ence of nodal failure in patients who und erwent lym ph nod e dissection alone was 26%, comp ared with 13% in those who were treated wit h lymph no de dissection and rad iatio n th erapy." Eich et al reported nodal relapse rates of 50 and 19% in patients who were treated with surgery alone and with surge ry plus adjuvant radi at ion th erapy, respectively." Adjuvant radiatio n th erapy has been shown to im prove diseasefree survival,11,12but not overall survival. Because of the high incidence ofnodal metastasis, elective treatment of the neck is warranted." :" In our study, only 10 patients were treated with lymp h node dissection, and more than half of th em (n = 6) were treated with adjuvan t nod al radiation th erapy. There was no significant difference in regional recurre nce in patients treated with lymph node dissection alone versus those treated with lymph node dissection and adjuvant radiation therapy (regional recurrence rates: 25 and 17%, respectively). With regard to th e cN-neck in the stage I/II gro up, our study showe d a trend toward better regional control 642· www.entjournal.com with either lymp h node dissection alone , lymp h no de dissection plus radiation therapy, or radiation therapy alone (82%) than without any treatment to the lymph nodes (60%) . Only a minority of our clinical stage II II patients und erwent lym ph node dissection; but of th at group, th e patien ts who underwen t both lymph no de dissection and rad iation th erapy achieved better regional control (4/4 ) tha n those treated with either lymph node dissection alone (2/3) or radiation therapy alone (3/4) . This suggests that radiation therapy may provide comparable con tro l to lymp h node dissection in th e cNneck.
In our study, a local or regional recurrence developed in 39% of patients (14/36) with a mean follow-up of 4.3 years. Our overall local (17%) and regional (28%) recurrence rates and distant metastasis rate (25%) are consis tent with the ranges reported by others: 18.2 to 39% for local recur rence, 13.6 to 65% for regional recurrences, and 9.1 to 40% for distant metastasis. 18 The role of chemotherapy in MCC remains con troversial, as vario us response rates have been reported." Chemotherapy has typically been reserved for patients with metastatic disease, but there has been an increased interest in its use for the tr eatment of patient s at high risk of spread. Chemotherapy is advocated by some authors in the initial treatm ent of MCC because of the high propensity that this malignan cy has for hematogenous spread and the high response rates associated with pallia tive chemotherapy.Y' :" A multivariate analysis by Poulsen et al showed a trend toward improved surviva l, bu t there wasno significant improvement in locoregional control or overall survival." Most NCCN institutions administer chemotherapy for distan t metastatic disease, and a minority of inst itution s use it as adjuvant therapy for local disease.15
Conclusion
MCC is a rare and aggressive epidermal can cer. In our . study, radiation therapy to the primary tumor site resulted in a local control rate of 95% in pat ients with head and neck MCC. Although most authors would recommend surgery wit h or without rad iation therapy to the cN+ neck, treatment of the cN-neck remains a dilemma in MCC, as it is with most cancers . We believe that there is a trend toward better regio nal con tro l of the cN-neck with the add ition of rad iation therapy. A multi-inst itutional prospective study is warranted to more clearly define the roles of surgery, radiation, and chemotherapy in this un com mon disease.
Based on our study and review of th e literature, we believe th at an aggressive approach to MCC of th e head and neck is app rop riat e. We feel it is in th e patient's best interest to be cared for by a multidisciplin ary management team that can add ress wide local excision, SLNB, lymph node dissection, radiation therapy, and chemoth erapy options.
